FindTrial
Sign In

Loperamide Hydrochloride

DRUG6 trials

Sponsors

Kartos Therapeutics Inc., Eastern Cooperative Oncology Group, Xian-Janssen Pharmaceutical Ltd., University of Pennsylvania, Ohio State University Comprehensive Cancer Center

Conditions

Advanced or Recurrent Endometrial CancerColorectal CancerDiarrheaHealthyLow Anterior Resection SyndromeOpioid Use DisorderPrimary MyelofibrosisRectal Carcinoma

Phase 1

Multi-System Analysis of Opioid Receptor Binding
Active, not recruitingNCT05528848
University of PennsylvaniaHealthy, Opioid Use Disorder
Start: 2022-09-20End: 2027-09-01Updated: 2026-03-30

Phase 2

A Phase 2/3 Study of Navtemadlin as Maintenance Therapy in Subjects with TP53WT Advanced or Recurrent Endometrial Cancer Who Responded to Chemotherapy
CompletedCTIS2022-502196-31-00
Kartos Therapeutics Inc.Advanced or Recurrent Endometrial Cancer
Start: 2023-08-21End: 2024-07-26Target: 140Updated: 2024-05-15

Phase 3

Octreotide Compared With Loperamide Hydrochloride for Chemotherapy-Related Diarrhea in Patients With Colorectal Cancer
CompletedNCT00003057
Eastern Cooperative Oncology GroupColorectal Cancer, Diarrhea
Start: 1997-03-26Target: 500Updated: 2023-06-18
Efficacy and Safety Study of Loperamide Hydrochloride/Simethicone Chewable Tablet in Treatment of Acute Diarrhea With Abdominal Discomfort and Flatulence
CompletedNCT02340481
Xian-Janssen Pharmaceutical Ltd.Diarrhea
Start: 2005-07-31End: 2006-05-31Updated: 2016-01-07
A Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
RecruitingCTIS2023-504724-25-00
Kartos Therapeutics Inc.Primary Myelofibrosis, Secondary Myelofibrosis (including but not limited to myelofibrosis post-Polycythemia Vera or post-Essential Thrombocythemia)
Start: 2024-10-16Target: 126Updated: 2025-10-06

Unknown Phase

A Bowel Management Program (Retrograde Rectal Enema) for the Treatment of Low Anterior Resection Syndrome in Rectal Cancer Patients
RecruitingNCT06424522
Ohio State University Comprehensive Cancer CenterLow Anterior Resection Syndrome, Rectal Carcinoma
Start: 2026-03-01End: 2028-12-31Target: 80Updated: 2026-01-20

Related Papers

POIESIS: a phase III study of add-on navtemadlin in JAK inhibitor-naïve myelofibrosis patients with a suboptimal response to ruxolitinib.
2026-03-07